Analysts forecast that DENTSPLY SIRONA Inc (NASDAQ:XRAY) will announce sales of $951.79 million for the current quarter, according to Zacks. Eight analysts have made estimates for DENTSPLY SIRONA’s earnings, with estimates ranging from $917.80 million to $1.02 billion. DENTSPLY SIRONA posted sales of $1.01 billion during the same quarter last year, which would indicate a negative year over year growth rate of 5.8%. The company is expected to issue its next earnings report on Friday, November 2nd.

According to Zacks, analysts expect that DENTSPLY SIRONA will report full-year sales of $3.99 billion for the current fiscal year, with estimates ranging from $3.95 billion to $4.13 billion. For the next year, analysts forecast that the business will post sales of $4.09 billion, with estimates ranging from $3.98 billion to $4.34 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.01. DENTSPLY SIRONA had a positive return on equity of 9.12% and a negative net margin of 39.62%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the company posted $0.65 earnings per share.

Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Monday, August 6th. Robert W. Baird downgraded DENTSPLY SIRONA from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $56.00 to $38.00 in a report on Tuesday, August 7th. BidaskClub raised DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. Barrington Research downgraded DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a report on Thursday, August 9th. Finally, HC Wainwright set a $40.00 target price on DENTSPLY SIRONA and gave the stock a “hold” rating in a report on Friday, August 31st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. DENTSPLY SIRONA currently has an average rating of “Hold” and a consensus target price of $51.50.

Shares of NASDAQ XRAY traded up $0.61 during mid-day trading on Wednesday, hitting $36.28. 4,193,512 shares of the stock traded hands, compared to its average volume of 2,566,803. The company has a quick ratio of 1.10, a current ratio of 1.69 and a debt-to-equity ratio of 0.31. DENTSPLY SIRONA has a 52 week low of $35.30 and a 52 week high of $68.98. The firm has a market capitalization of $7.93 billion, a PE ratio of 13.64, a P/E/G ratio of 2.07 and a beta of 1.20.

Several large investors have recently made changes to their positions in XRAY. Orbimed Advisors LLC lifted its holdings in shares of DENTSPLY SIRONA by 963.8% during the second quarter. Orbimed Advisors LLC now owns 2,393,500 shares of the medical instruments supplier’s stock valued at $104,763,000 after purchasing an additional 2,168,500 shares in the last quarter. Veritas Asset Management LLP lifted its holdings in shares of DENTSPLY SIRONA by 19.9% during the second quarter. Veritas Asset Management LLP now owns 10,092,601 shares of the medical instruments supplier’s stock valued at $441,753,000 after purchasing an additional 1,674,946 shares in the last quarter. Nuance Investments LLC lifted its holdings in shares of DENTSPLY SIRONA by 134.6% during the second quarter. Nuance Investments LLC now owns 2,174,311 shares of the medical instruments supplier’s stock valued at $95,170,000 after purchasing an additional 1,247,670 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its holdings in shares of DENTSPLY SIRONA by 43.1% during the second quarter. Thompson Siegel & Walmsley LLC now owns 2,213,839 shares of the medical instruments supplier’s stock valued at $96,899,000 after purchasing an additional 667,148 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of DENTSPLY SIRONA by 18.2% during the second quarter. Bank of America Corp DE now owns 3,112,821 shares of the medical instruments supplier’s stock valued at $136,248,000 after purchasing an additional 479,365 shares in the last quarter. 97.56% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Further Reading: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.